Hepatocellular Carcinoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight

(Albany, USA) As per DelveInsight's assessment, globally, about 90+ key pharma and biotech companies are working on 95+ pipeline drugs in the Hepatocellular Carcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Hepatocellular Carcinoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatocellular Carcinoma Therapeutics Market.

The report provides a detailed description of the Hepatocellular Carcinoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Hepatocellular Carcinoma Clinical Trial Activities and Regulatory Developments in the domain @ Hepatocellular Carcinoma Pipeline Analysis - https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Hepatocellular Carcinoma Pipeline are:
• Hepatocellular Carcinoma Companies across the globe are diligently working toward developing novel Hepatocellular Carcinoma treatment therapies with a considerable amount of success over the years.
• Hepatocellular Carcinoma companies working in the treatment market are Polaris Pharmaceuticals, Sumitomo Pharma, Surface Oncology, Oxford BioTherapeutics, OriCell Therapeutics, Tarus Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Shanghai Henlius Biotech, Tvardi Therapeutics, SCG Cell Therapy, AVEO Oncology, Sinocelltech, GlaxoSmithKline, Iterion Therapeutics, Array BioPharma, Beijing SyngenTech, Antengene Corporation, Shenogen Pharma, Novartis Oncology, Yiviva, Taizhou Hanzhong Pharmaceuticals, CStone Pharmaceuticals, Akeso Biopharma, Can-Fite BioPharma, Virogin Biotech, Eutilex, SillaJen Biotherapeutics, Guangdong ProCap Zoom Biosciences, Chugai Pharmaceutical, and others, are developing therapies for the Hepatocellular Carcinoma treatment
• Emerging Hepatocellular Carcinoma therapies in the different phases of clinical trials are Namodenoson, SRF388, Porustobart, Fisogatinib, STP705, and others are expected to have a significant impact on the Hepatocellular Carcinoma market in the coming years.
• In February 2025, Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma (HCC).
• In February 2025, Gene therapy-based anticancer candidate RZ-001 receives fast track in hepatocellular carcinoma following glioblastoma. Alznomics' gene therapy-based anticancer drug candidate has been designated as fast track by the U.S. Food and Drug Administration (FDA) for hepatocellular carcinoma.
• In January 2025, Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), based on results from the Phase 3 CheckMate -9DW trial. The CHMP opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines in the European Union (EU).
• In August 2024, Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) as potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC), based on results from the Phase 3 CheckMate -9DW trial. The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 21, 2025.

Hepatocellular Carcinoma (HCC) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Hepatocellular Carcinoma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Hepatocellular Carcinoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hepatocellular Carcinoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Hepatocellular Carcinoma Therapeutics Domain @ Hepatocellular Carcinoma FDA Approvals and Advancements - https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatocellular Carcinoma (HCC) Therapeutics Analysis
About 90+ notable companies are actively involved in developing therapies for Hepatocellular Carcinoma (HCC). Among them, Can-Fite BioPharma stands out as a key player, advancing its HCC drug candidates to the most advanced stage, Phase III.

Hepatocellular Carcinoma Companies in the Therapeutics Market Include:
Can-Fite BioPharma (NYSE: CANF), Sinocelltech (SHA: 688520), AVEO Oncology (Nasdaq: AVEO), Oxford BioTherapeutics (Private), Beijing SyngenTech (Private), Surface Oncology (Nasdaq: SURF), Novartis Oncology (SWX: NOVN), Array BioPharma (acquired by Pfizer, formerly Nasdaq: ARRY), Taizhou Hanzhong Pharmaceuticals (Private), Akeso Biopharma (HKEX: 9926), Shanghai Henlius Biotech (HKEX: 2696), Chugai Pharmaceutical (TYO: 4519), CStone Pharmaceuticals (HKEX: 2616), Shenogen Pharma (Private), GlaxoSmithKline (LSE: GSK), Tarus Therapeutics (Private), Tvardi Therapeutics (Private), Virogin Biotech (Private), Yiviva (Private), Chia Tai Tianqing Pharmaceutical Group (Subsidiary of Sino Biopharmaceutical Limited, HKEX: 1177), Antengene Corporation (HKEX: 6996), Iterion Therapeutics (Private), Sumitomo Pharma (TYO: 4506), SillaJen Biotherapeutics (KOSDAQ: 215600), SCG Cell Therapy (Private), Guangdong ProCap Zoom Biosciences (Private), Eutilex (KONEX: 263050), Polaris Pharmaceuticals (Private), and OriCell Therapeutics (Private) are the leading pharma giants shaping the landscape of the Hepatocellular Carcinoma Therapeutic Market.

Emerging and Marketed Hepatocellular Carcinoma Therapies Covered in the Report Include:
• Namodenoson: Can-Fite BioPharma
• SRF388: Surface Oncology
• Porustobart: Harbour BioMed
• Fisogatinib: CStone Pharmaceuticals
• STP705: Sirnaomics
• And Many Others

Get an in-depth Assessment of the Emerging Therapies and Hepatocellular Carcinoma Companies Actively Working in the Market @ Hepatocellular Carcinoma Drugs in Pipeline - https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatocellular Carcinoma Drugs Uptake
The Report Covers the Emerging Hepatocellular Carcinoma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Request for sample report @ https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Route of Administration
Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Request for Sample PDF to Understand More About the Hepatocellular Carcinoma Treatment Outlook and Future Perspectives @ Hepatocellular Carcinoma Drugs and Therapies - https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Hepatocellular Carcinoma Current Treatment Patterns
4. Hepatocellular Carcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hepatocellular Carcinoma Late-Stage Products (Phase-III)
7. Hepatocellular Carcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hepatocellular Carcinoma Discontinued Products
13. Hepatocellular Carcinoma Product Profiles
14. Hepatocellular Carcinoma Companies
15. Hepatocellular Carcinoma Drugs
16. Dormant and Discontinued Products
17. Hepatocellular Carcinoma Unmet Needs
18. Hepatocellular Carcinoma Future Perspectives
19. Hepatocellular Carcinoma Analyst Review
20. Appendix
21. Report Methodology

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.